From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve.
about
Modeling leukocyte trafficking at the human blood-nerve barrier in vitro and in vivo geared towards targeted molecular therapies for peripheral neuroinflammationPredicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic NeuritisInflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention.Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II moleculesCCR2 gene deletion and pharmacologic blockade ameliorate a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome[Guillain-Barré syndrome after exposure to influenza].α(M)β(2)-integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barré syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro.Interleukin-10 overexpression promotes Fas-ligand-dependent chronic macrophage-mediated demyelinating polyneuropathy.The role of chemokines in Guillain-Barré syndrome.Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-β in macrophages.Pathogenesis and treatment of immune-mediated neuropathies.Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barré syndrome.FoxP3+ regulatory T cells determine disease severity in rodent models of inflammatory neuropathies.Deregulated Fcγ receptor expression in patients with CIDP.Myelin ultrastructure of sciatic nerve in rat experimental autoimmune neuritis model and its correlation with associated protein expression.Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathiesTranslational strategies in peripheral neuroinflammation and neurovascular repair.Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy.Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.Treatment in inflammatory neuropathies.Novel treatment for immune neuropathies on the horizon.Recent developments and future directions in Guillain-Barré syndrome.Concepts for regulation of axon integrity by enwrapping glia.Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.The pathogenic relevance of αM-integrin in Guillain-Barré syndrome.Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy.Targeting lysophospholipid signaling as a therapeutic approach towards improved peripheral nerve regeneration.Novel pathomechanisms in inflammatory neuropathies.Behavioral, electrophysiological, and histopathological characterization of a severe murine chronic demyelinating polyneuritis model.Expression and function of the inhibitory Fcγ-receptor in CIDP.Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies
P2860
Q27303465-A63575A4-379F-4BEA-9961-F7DD659B4E52Q27320796-4DCE7B64-A43A-4259-A272-F7B1D9C24879Q27322544-97F82FA5-FFA8-482F-9DC4-127527BE8B9FQ28478607-29A81C41-36CB-4E1A-AE06-0E4714C4BF75Q28540888-E5CA1C07-0E60-4645-8F28-0384D5B9F1FDQ30415924-5C75179A-09B5-4BAF-B4F3-C750F41E7857Q30524065-4CF651B6-0383-4CDE-9178-819FF7E68DA3Q33505676-A2F4AA10-77C7-45FE-8BA6-9BEFE9131A96Q33624382-A25192FA-1DCD-4867-8692-8FC36B8D3A11Q34063671-0AA7A019-7BD3-4D66-8357-278840A48D9EQ34409385-F39E6F39-5E14-467C-BC34-13B36231579EQ34431762-E9AA2AF3-9100-446F-94C7-C2837B7345ABQ35305030-746740F8-141E-4BDB-9FBF-079BA3280203Q35991588-C75B2482-AA0E-424C-A630-C9A10BEF712DQ36014183-BEE879E7-8775-4C29-8FD4-35C5211D7448Q36266469-16EA9B7E-3CBB-4FC4-B073-21ADF677C9F3Q36345917-72D4A0FB-5E01-48F8-BBEC-FBE376EA1613Q36802945-88428CF4-F615-4815-B2D3-C92CFA7A3DC4Q37140095-664CF248-1B44-43E4-A433-338CD7F3A6E6Q37557375-F60B05E7-10FC-458E-BF69-8F2B4CBECB5CQ37733512-46747F25-9AA3-42CC-9B6F-B7A371F35F59Q37892641-90931ADF-06AB-4158-8F35-862C44C73257Q38070887-76FD88B1-9467-4410-AACF-2D8761548532Q38175969-DAF9005F-112A-4CA3-9BED-A1FF9B733D07Q39434973-582815FA-4D03-472E-A8A9-A60A453FBCA2Q39558493-24851362-6852-4702-A8CF-4ADBF852EECBQ40444924-6BD461C8-C587-4897-BD8D-5BED822F050EQ40462969-E72917BA-0E16-417A-83BE-D025801F236EQ47126672-73CCAC83-862B-4929-8D70-4CFC5FF62D88Q49470841-97307952-BB54-4E06-B903-A287214F24FCQ51002069-D4A9D3DC-1813-4D1F-80B5-DE5BEC3B3B55Q57300562-41431814-5C07-46F1-BA8E-C3991744F7D8
P2860
From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
From bench to bedside--experim ...... the inflamed peripheral nerve.
@ast
From bench to bedside--experim ...... the inflamed peripheral nerve.
@en
type
label
From bench to bedside--experim ...... the inflamed peripheral nerve.
@ast
From bench to bedside--experim ...... the inflamed peripheral nerve.
@en
prefLabel
From bench to bedside--experim ...... the inflamed peripheral nerve.
@ast
From bench to bedside--experim ...... the inflamed peripheral nerve.
@en
P2860
P50
P356
P1476
From bench to bedside--experim ...... the inflamed peripheral nerve.
@en
P2860
P2888
P304
P356
10.1038/NCPNEURO0452
P577
2007-04-01T00:00:00Z
P6179
1002926579